<DOC>
	<DOCNO>NCT00841516</DOCNO>
	<brief_summary>This trial perform immunological histological evaluation specific immunotherapy aluminium hydroxide-adsorbed recombinant hypoallergenic derivative major birch pollen allergen , rBet v1-FV</brief_summary>
	<brief_title>Immunological Histological Evaluation Specific Immunotherapy With Recombinant Hypoallergenic Derivative</brief_title>
	<detailed_description>Type I allergy immune-disorder stem formation IgE antibodies proteins glycoprotein plant , insect , animal fungi , normally consider harmless . The cross-linking specific IgE antibody effector cell allergens activates immunological cascade lead symptom Type I allergy include rhinitis , conjunctivitis , asthma , anaphylactic shock . Allergic Rhinitis common chronic atopic disease associate considerable cost co-morbidity . Seasonal allergic rhinitis ( SAR ) , trigger pollen tree , grass weed , characterize sneezing , nasal congestion , nasal itching , rhinorrhea , pruritic , watery , red eye . Recombinant preparation offer various advantage base natural allergen extract . Recombinant protein produce highly purified form pharmaceutical quality ; proteins molecularly define thus ensure product consistency minimise problem related allergen extract standardisation ; preparation include protein consider relevant specific immunotherapy ; risk contamination allergenic material exclude ; whole production process design exclude risk factor introduction infectious agent ; relative dosage individual component final preparation optimise favour well clinical efficacy . Allergy vaccination ( AV ) mediate immune response allergen exposure alter TH2 response favour TH1 T-cell response , increase IgG production decrease production inflammatory cytokine . rBet v1-FV AV design enhance beneficial immune response . The investigational product demonstrate efficacy good tolerability one previous pivotal Phase III two previous Phase II study .</detailed_description>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Positive SPT Positive EAST Positive specific provocation test Serious chronic diseases Other perennial allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Specific immunotherapy</keyword>
	<keyword>SIT</keyword>
	<keyword>SCIT</keyword>
	<keyword>recombinant</keyword>
	<keyword>Type 1 - Allergy</keyword>
</DOC>